Adult height in children born small for gestational age (SGA) with persistent short stature (SGA-SS). Growth hormone treatment outcomes from data of the Czech countrywide REPAR database
Authors:
Toni Ledjona 1,AnetaKodytková 1; Plachý Lukáš 1; Jírová Barbora 1; Hainerová Aldhoon Irena 2; Aleksijevi Darina 3; Černá Jana 4; Dvořáková Marcela 5; El-Lababidi Eva 2; Kalvachová Božena 5; Kocourková Kamila 6; Kotvalová Ivana 7; Magnová Olga 8; Novotná Dana 8; Obermannová Barbora 1; Pomahačová Renata 9; Průhová Štěpánka 1; Souček Ondřej 1; Strnadel Jiří 4; Šíchová Lucie 10; Škvor Jaroslav 10; Šnajderová Marta 1; Šumník Zdeněk 1; Zapletalová Jiřina 3; Šilar Jiří 11; Koloušková Stanislava 1; Lebl Jan 1
Authors place of work:
Pediatrická klinika, 2. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice v Motole, Praha
1; Klinika dětí a dorostu, 3. lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Královské Vinohrady, Praha
2; Dětská klinika, Lékařská fakulta, Univerzita Palackého a Fakultní nemocnice Olomouc
3; Klinika dětského lékařství, Lékařská fakulta, Ostravská univerzita a Fakultní nemocnice Ostrava
4; Endokrinologický ústav, Praha
5; Dětské oddělení, Nemocnice České Budějovice
6; Dětská klinika, Lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Hradec Králové
7; Pediatrická klinika, Lékařská fakulta, Masarykova univerzita a Fakultní nemocnice Brno ¨
8; Dětská klinika, Lékařská fakulta, Univerzita Karlova a Fakultní nemocnice Plzeň
9; Dětská klinika, Masarykova nemocnice, Krajská zdravotní, a. s., Ústí nad Labem
10; Institut biostatistiky a analýz, s. r. o., Brno #tyto dvě autorky přispěly ke vzniku článku stejným dílem
11
Published in the journal:
Čes-slov Pediat 2023; 78 (S3): 22-29.
Category:
Original Papers
doi:
https://doi.org/10.55095/CSPediatrie2023/059
Summary
Of children born small for gestational age (SGA) with birth weight and/or birth length below −2 SD, about 10% fail to catch-up after birth. These children remain short over childhood (with height standard deviation score [ht-SDS] below −2.5 SDS) and end up as short adults. They are assigned as SGA-SS (small for gestational age with short stature). European Medicine Agency approved growth hormone therapy in SGA-SS already in 2003.
Out of 1502 SGA-SS children that are registered in the Czech national database of growth hormone recipients REPAR, 397 children (221 boys) already completed growth and achieved near-final height. Growth hormone therapy (median dose 0.034 mg/kg/day) was initiated at age 8.5 years in boys (median; P5-95: 3.2-15.0) and 7.3 years in girls (3.9-13.5). The mean ht-SDS at treatment initiation was −3.21 (SD: 0.91). Treatment was terminated at age 16.2 years in boys (median; P5-95: 14.0-18.7) and 14.3 years in girls (12.4-17.3).
By treatment termination, the patients have had gained 1.59 ht-SDS (mean) and have achieved near-final height −1.62 ht-SDS (SD: 0.97; p<0.0001 if compared to pre-treatment). Thus, majority of patients exceeded −2 SDS at treatment completion and achieved height within normal limits. After adjusting for ht-SDS at age 18 years, their height corresponded to ht-SDS −2.30 (SD: 1.09; p < 0.0001 if compared to pre-treatment). Growth hormone therapy was successful even after this adjustment that mildly underestimates the treatment effect, and led to mean height increase of 0.91 ht-SDS.
Analysis results of the REPAR database confirm efficacy of growth hormone therapy in SGA-SS children and its potential to significantly improve the adult height.
Zdroje
1. Brundtland GH. From the World Health Organization. Reducing risks to health, promoting healthy life. JAMA 2002; 288(16): 1974.
2. Lee AC, Katz J, Blencowe H, et al. National and regional estimates of term and preterm babies born small for gestational age in 138 low-income and middle-income countries in 2010. Lancet Glob Health 2013; 1: e26–e36
3. Lee PA, Chernausek SD, Hokken-Koelega AC, Czernichow P; International Small for Gestational Age Advisory Board. International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24– October 1, 2001. Pediatrics 2003; 111(6 Pt 1): 1253–1261.
4. Lawrence C, Fryer JG, Karlberg P, et al. Modelling of reference values for size at birth. Acta Paediatr Scand 1989; Suppl 350: 55–69.
5. Zeve D, Regelmann MO, Holzman IR, Rapaport R. Small at birth, but how small? The definition of SGA revisited. Horm Res Paediatr 2016; 86(5): 357–360.
6. Xu H, Simonet F, Luo ZC. Optimal birth weight percentile cut-offs in defining small- or large-for-gestational-age. Acta Paediatr 2010; 99(4): 550–555.
7. Saenger P, Czernichow P, Hughes I, Reiter EO. Small for gestational age: short stature and beyond. Endocr Rev 2007; 28: 219–251.
8. Clayton PE, Cianfarani S, Czernichow P, et al. Management of the child born small for gestational age through to adulthood: a consensus statement of the International Societies of Pediatric Endocrinology and the Growth Hormone Research Society. J Clin Endocrinol Metab 2007; 92: 804–810.
9. Pfäffle R, Knüpfer M, Göbert M, et al. Growth patterns of children with short stature in adulthood according to auxological status and maturity at birth. J Clin Endocrinol Metab 2022; 107: 3320–3327
10. Groene SG, Gremmen IJ, van Zwet EW, et al. Fetal growth restriction inhibits childhood growth despite catch-up in discordant identical twins: an observational cohort study Eur J Endocrinol 2023; 189: 183–189.
11. Lebl J, Koloušková S, Průhová Š, Zapletalová J. Léčba růstovým hormonem – historie, současnost a budoucnost. Farmakoter Revue 2017; 2: 224–230.
12. Kodytková A, Al Lababidi E, Čermáková I, et al. Analýza dat z celostátního registru pacientů léčených růstovým hormonem REPAR. Ces-Slov Pediat 2020; 75: 205–212.
13. Sas T, de Waal W, Mulder P, et al. Growth hormone treatment in children with short stature born small for gestational age: 5-year results of a randomized, double-blind, dose-response trial. J Clin Endocrinol Metab 1999; 84: 3064–70.
14. Boguszewski M, Albertsson-Wikland K, Aronsson S, et al. Growth hormone treatment of short children born small-for-gestational-age: Nordic Multicentre Trial. Acta Paediatr 1998; 87: 257–63.
15. Karlberg J, Albertsson-Wikland K. Growth in full-term small-for-gestational-age infants: from birth to final height. Pediatr Res 1995; 38: 733–739.
16. Ruiz RA, Pérez AB, Leiva-Gea I, et al. Factors influencing height gain in children born small for gestational age treated with recombinant growth hormone: what extent is puberty involved? Ther Adv Endocrinol Metab 2022; 13: 1–14.
17. Adler E, Lambert AS, Bouvattier C, et al. Determinants of final height in patients born small for gestational age treated with recombinant growth hormone. Horm Res Paediatr 2021; 94: 52–62
18. Bláha P, Vignerová J, Riedlová J, et al. VI. celostátní antropologický výzkum dětí a mládeže 2001. Ces-Slov Pediat 2003; 58: 766–770.
19. Wakeling EL, Brioude F, Lokulo-Sodipe O, et al. Diagnosis and management of Silver-Russell syndrome: first international consensus statement. Nat Rev Endocrinol 2017; 13: 105–124.
20. Lebl J, Lebenthal Y, Kolouskova S, et al. Metabolic impact of growth hormone treatment in short children born small for gestational age. Horm Res Paediatr 2011; 76: 254–61.
21. Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, et al. International Consensus Guideline on Small for Gestational Age: Etiology and management from infancy to early adulthood. Endocr Rev 2023; 44: 539–565.
22. de Zegher F, Ong KK, Ibáñez L, Dunger DB. Growth hormone therapy in short children born small for gestational age. Horm Res 2006; 65(Suppl 3): 145–52.
23. Ranke MB, Lindberg A, Cowell CT, et al. Prediction of response to growth hormone treatment in short children born small for gestational age: Analysis of data from KIGS (Pharmacia International Growth Database). J Clin Endocrinol Metab 2003; 88: 125–31.
24. Van Pareren Y, Mulder P, Houdijk M, et al. Adult height after long-term, continuous growth hormone (GH) treatment in short children born small for gestational age: results of a randomized, double-blind, dose-response GH trial. J Clin Endocrinol Metab 2003; 88: 3584–90.
25. Carel J-C, Chatelain P, Rochiccioli P, Chaussain J-L. Improvement in adult height after growth hormone treatment in adolescents with short stature born small for gestational age: results of a randomized controlled study. J Clin Endocrinol Metab 2003; 88: 1587–93.
26. Dahlgren J, Wikland KA; Swedish Study Group for Growth Hormone Treatment. Final height in short children born small for gestational age treated with growth hormone. Pediatr Res 2005; 57: 216–22.
27. van Dijk M, Bannink EMN, van Pareren YK, et al. Risk factors for diabetes mellitus type 2 and metabolic syndrome are comparable for previously growth hormone-treated young adults born small for gestational age (sga) and untreated short SGA controls. J Clin Endocrinol Metab 2007; 92: 160–5.
28. Lem AJ, van der Kaay DCM, de Ridder MAJ, et al. Adult height in short children born SGA treated with growth hormone and gonadotropin releasing hormone analog: results of a randomized, dose-response GH trial. J Clin Endocrinol Metab 2012; 97: 4096–105.
29. Thomas M, Beckers D, Brachet C, et al. Adult height after growth hormone treatment at pubertal onset in short adolescents born small for gestational age: results from a Belgian registry-based study. Int J Endocrinol 2018; 2018: 6421243.
30. Li X, Yao R, Chang G, et al. Clinical profiles and genetic spectra of 814 chinese children with short stature. J Clin Endocrinol Metab 2022; 107: 972–985.
31. Toni L, Plachy L, Dusatkova P, et al. The genetic landscape of children born small for gestational age with persistent short stature (SGA-SS). Horm Res Paediatr 2023. doi: 10.1159/000530521
32. Kodytková A, Toni L, Plachý L, et al. Prepubertální růst a pubertální růstový výšvih dětí, které se narodily malé na svůj gestační věk (SGA) s malou výškou v dětství (SGA-SS). Vliv léčby růstovým hormonem z dat české národní databáze REPAR. Ces-Slov Pediat 2023; 78(S3): S30–36.
Štítky
Neonatology Paediatrics General practitioner for children and adolescentsČlánok vyšiel v časopise
Czech-Slovak Pediatrics
2023 Číslo S3
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
Najčítanejšie v tomto čísle
- Anorexia nervosa from an endocrinologist's point of view
- Multiple endocrine neoplasia in childhood
- Current view on the diagnostics of growth hormone deficiency in childhood and adolescence
- Pubertal growth in children born small for gestational age (SGA) with persistent short stature (SGA-SS). Growth hormone treatment outcomes from data of the Czech countywide REPAR database